NYD-SP18 Inhibitors
NYD-SP18 inhibitors belong to a specific class of chemical compounds characterized by their ability to interact with and inhibit the function of the protein known as NYD-SP18. The NYD-SP18 protein is part of a larger family of proteins that are involved in various cellular processes. Inhibitors of this protein are designed based on the understanding of the protein's structure and function. These compounds typically work by binding to the active site or another critical region of the protein, effectively blocking its natural interaction with other cellular components. This action alters the protein's activity, leading to changes in the biochemical pathways in which the protein is involved.
Chemically, NYD-SP18 inhibitors can be diverse, encompassing a range of molecular frameworks and possessing various functional groups that contribute to their inhibitory activity. Their design is often the result of extensive structure-activity relationship (SAR) studies, where small modifications to the chemical structure can lead to significant changes in binding affinity and selectivity for the NYD-SP18 protein. In the development of these inhibitors, researchers employ techniques such as X-ray crystallography or NMR spectroscopy to determine the precise interaction between the inhibitor and the protein at the atomic level. Such detailed structural information is crucial for the rational design of these compounds to enhance their efficacy in inhibiting the target protein. Moreover, the physicochemical properties of these inhibitors, such as solubility, stability, and permeability, are optimized to ensure that they can effectively reach and interact with the NYD-SP18 protein within the complex cellular environment.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, LY294002 leads to downregulation of the PI3K/AKT signaling pathway. Since NYD-SP18 is associated with cell signaling mechanisms that could be influenced by PI3K activity, the inhibition of this pathway would result in a decrease in NYD-SP18-mediated signaling events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As an inhibitor of MEK1/2, PD98059 blocks the MAPK/ERK pathway. NYD-SP18, which may interact with components of this pathway, would have decreased functional activity due to the suppression of ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound selectively inhibits p38 MAP kinase, which is involved in cellular responses to stress and cytokines. Inhibition of p38 may indirectly reduce NYD-SP18 activity if NYD-SP18 is part of stress response signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, Wortmannin disrupts the PI3K/AKT pathway similar to LY294002. As such, NYD-SP18-dependent processes that are PI3K/AKT-related would be diminished. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin can suppress the mTOR signaling pathway, which is crucial for cell growth and proliferation. If NYD-SP18 is implicated in these processes, its functional activity would be negatively impacted by Rapamycin. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, thereby affecting the JNK signaling pathway. If NYD-SP18 is involved in JNK-mediated cellular events, this inhibition would lead to a reduction in its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, preventing the activation of MAPK/ERK pathway. NYD-SP18 activity that is reliant on this pathway would be indirectly inhibited by U0126. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A selective inhibitor of Src family tyrosine kinases, PP2 can disrupt signaling pathways requiring Src kinase activity. If NYD-SP18 is functionally connected to Src-mediated pathways, its activity would be decreased by PP2. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, Bortezomib may affect the degradation pathways of proteins. If the stability or turnover of NYD-SP18 relies on proteasome activity, Bortezomib would indirectly decrease its functional activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor with broad specificity, including Src kinases. Dasatinib could reduce NYD-SP18 activity by inhibiting tyrosine kinase-dependent signaling pathways that may involve NYD-SP18. | ||||||